Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Novacyt  /  nieuws Novacyt

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

  • 0,830 19 apr 2024 17:35
  • +0,080 (+10,67%) Dagrange 0,735 - 0,867
  • 1.517.074 Gem. (3M) 147,5K

nieuws Novacyt

219 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 »» | Laatste | Omlaag ↓
  1. forum rang 10 voda 28 juli 2022 08:10
    Novacyt S.A.
    (“Novacyt”, the “Company” or the “Group”)
    Launch of research - use - only adeno virus F41 assay

    The assay has been developed by Novacyt to support research efforts follow ing
    a recent increase in cases of acute hepatitis in children

    Paris, France and Camberley, UK – 2 8 July 2022 – Novacyt ( EURONEXT GROWTH:
    ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the
    launch of a research - use - only (RUO) polymerase chain reaction (PCR) assay for the
    detection of a denovirus F41 , in response to recent cases of acute hepatitis in children . This
    launch expand s Novacyt’s genesig ® real - time PCR diagnostic product portfolio and is in
    line with the Company’s strategy to maintain its position as a global first responder in
    infectious diseases.

    Adenoviruses are a large group of viruses divided into several species and subtypes. They
    are the cause of several illnesses, usually exhibiting as colds or flu - like illness, which may
    also cause gastrointestinal symptoms such as diarrhoea. Adenoviruses are primarily
    spread via respiratory droplets; however, they can also be spread by faecal routes.
    Ongoing investigations, particularly in the UK, have identified adenovirus infection in
    children , and in particular, adenovirus F41 in several cases.

    This assay has been developed in two forms, genesig ® Advanced and genesig ® Easy,
    designed for in vitro detection of adenovirus species F serotype 41 genomes, without
    detecting any closely related adenovirus sequences. Novacyt’s genesig ® Advanced assay
    is configured for use with any open test platform, including Novacyt’s MyGo instruments,
    the genesig ® Easy assay is suitable for use on the Company’s q16 and q32 instruments.
    Novacyt, through its specialist bioinformatics surveillance expertise, continually tracks the
    changing pathology of diseases worldwide, and will regularly review the detection profile
    of assays , ensuring that new versions are developed if necessary.

    David Allmond, Chief Executive Officer of Novacyt, commented:
    “ Our RUO adenovirus F41 assay has been developed in response to recent cases of acute
    hepatitis in children to support research efforts in determining the cause of this severe
    disease. The launch of this new assay , as well as our recent assay for the detection of the
    Monkeypox virus, subsequently declared a global health emergency by the WHO, reinforce
    Novacyt’s positionas a global first responder, as well as our commitment to expanding
    our portfolio in infectious diseases, both inline with our stated strategy. Our extensive
    leading RUO portfolio consists of over 850 products, span ning veterinary, food,
    environment , and human health research. The portfolio is a key part of our core business ?
    and serves as an innovation engine for the Company as we transition beyond the Covid -
    19 pandemic.”
    – End -

    novacyt.com/wp-content/uploads/2022/0...
  2. forum rang 10 voda 4 augustus 2022 08:08
    04 Aug Launch of Novacyt’s first fully lyophilised PROmate® assays
    in Board, News, Novacyt Group

    New freeze-dried, direct-to-PCR assays extend the global reach of Novacyt’s PCR portfolio with ability to be transported at ambient temperatures
    Two PROmate® lyophilised assays initially launched for COVID-19, with a broader portfolio of lyophilised direct-to-PCR assays in development

    novacyt.com/wp-content/uploads/2022/0...
  3. forum rang 10 voda 15 september 2022 13:42
    15 Sep Notice of Half Year 2022 Results and Investor Presentation
    in Board, Novacyt Group

    novacyt.com/wp-content/uploads/2022/0...

    Paris, France and Camberley, UK – 15 September 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its unaudited financial results for the six months ended 30 June 2022 on Thursday, 29 September 2022.
  4. forum rang 10 voda 29 september 2022 08:53
    29 Sep Half year 2022 results
    in Board, Novacyt Group
    Significant progress against post-COVID-19 growth strategy to offset expected decline in COVID-19 sales

    Paris, France and Camberley, UK – 29 September 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the six months ended 30 June 2022.

    novacyt.com/wp-content/uploads/2022/0...
  5. forum rang 10 voda 26 oktober 2022 07:05
    www.zonebourse.com/cours/action/NOVAC...

    Novacyt SA

    ("Novacyt", the "Company" or the "Group")

    UK CTDA Regulatory Approval of genesig ® SARS-CoV-2 Winterplex ® 3 -Gene Test Panel

    A multiplex PCR test for the detection of winter viruses, including the

    SARS-CoV-2, influenza A and B, and RSV

    Paris, France and Camberley, UK - October 26, 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its genesig ® Real-Time PCR SARS-CoV-2 Winterplex test panel ® 3G (Winterplex ® 3G) has been approved in the UK by the UK Health Safety Agency (Coronavirus Test Device Approvals) (Amendment) ("CTDA") Regulations 2021, becoming the company's sixth PCR test to be added to the CTDA Registry of Approved COVID-19 Diagnostic Products .

    Winterplex ® 3G is a high-throughput multiplex screening test (with 96 reactions per kit) for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-

    (especially the detection of ORF1ab, S and M gene targets) from oropharyngeal, nasopharyngeal or saliva samples.
    This approval comes ahead of winter virus season in the northern hemisphere and means the company can now sell Winterplex® 3G in the UK. The Winterplex® 3G enables healthcare systems to differentiate between common respiratory infections that present with similar symptoms. Faced with the spread of winter viruses, Novacyt continues to monitor all strains of influenza A, influenza B, RSV and SARS-CoV-2 through its bioinformatics monitoring program.

    David Allmond, CEO of Novacyt Group, commented:

    “We are proud that Winterplex® 3G has been approved under UK CTDA regulations. This product is a combined test which offers the advantage of testing several seasonal viruses at the same time, saving time and requiring only a single patient sample We believe this is important as the diagnostics market tends to favor respiratory panels over COVID-19 specific tests due to concerns about the parallel increase in COVID-19 cases and flu this winter. This latest approval positions us well with our consolidated COVID-19 portfolio for potential future outbreaks.as we continue to focus on our expanded respiratory product offering as part of our growth strategy."

    The status of applications currently submitted to the CTDA by the Company is as follows:

    #

    Product Name
    Current CTDA Status
    1
    genesig® COVID -19Real-Time PCR
    Approved November 2021
    2
    PROmate® COVID -19 2G (q32)
    Approved February 2022
    3
    PROmate® COVID -19 1G (q32)
    Approved in April 2022
    4
    PROmate® COVID -19 1G (q16)
    Approved May 2022
    5
    exsig™ COVID-19 Direct
    Approved July 2022
    6
    genesig ® Real-time PCR SARS-CoV-2 Winterplex
    Approved October 20, 2022
    7
    genesig ® COVID-19 3G Real-Time PCR
    8
    PathFlow® COVID -19 Rapid Antigen Pro
    Evaluation in progress
    9
    PathFlow® COVID -19 Rapid Antigen Self-Test

    - End -
  6. forum rang 10 voda 28 oktober 2022 06:56
    This is a correction to the “ UK Approval of genesig® SARS - CoV - 2 Winterplex® 3G ” announcement
    published at 7:00am on 26 October 2022 (RNS number 0989E) which incorrectly stated that
    Winterplex® 3G could use sputum and nasopharyngeal samples rather than anterior nasal samples
    (in addition to oropharyngeal samples ) for the detection of influenza A, influenza B, respiratory
    syncytial virus (RSV), and SARS - CoV - 2 (COVID - 19) (specifically the detection of ORF1ab, S and M
    genes targets).
    All other information remains unchanged. The full corrected announcement is included below.

    Zie de pdf.
    Bijlage:
  7. forum rang 10 voda 10 november 2022 08:28
    10 Nov Directorate change
    in Board, Novacyt Group

    Paris, France and Camberley, UK – 10 November 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that David Allmond is stepping down as Chief Executive Officer (CEO) and a member of the Board of Novacyt, with immediate effect, to enable him to pursue other business opportunities. James McCarthy, currently the Company’s Chief Financial Officer (CFO), will assume the role of Acting CEO until a successor is appointed. Steve Gibson, Group Finance Director, will take on a substantial part of the CFO responsibilities to assist James in this period.

    The Company remains focused on executing its post-COVID-19 growth strategy to become a leading, global clinical diagnostics company in the fight against infectious diseases through product portfolio expansion, geographic expansion, and business development.

    Directorate change

    novacyt.com/directorate-change/
  8. forum rang 10 voda 6 december 2022 08:55
    Novacyt S.A.

    ("Novacyt", the "Company" or the "Group")

    Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation

    Paris, France and Eastleigh, UK - 6 December 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's genesig® COVID-19 3G Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"), making it the Company's seventh PCR test to be added to the CTDA register of approved COVID-19 diagnostic products.

    The genesig® COVID-19 3G test, CE marked in April 2021, is designed to detect three separate SARS-CoV-2 gene targets (ORF1ab, M gene, and S genes) from combined nasal and oropharyngeal sample types. As seen during the COVID-19 pandemic, the prevalence of mutations with biological significance within the spike protein of SARS-CoV-2 meant the need to test for more than one gene target at a time increased.

    James McCarthy, Acting Group CEO of Novacyt, commented:

    "The approval of our COVID-19 3G test, our seventh product to be approved under the UK's CTDA legislation, reinforces the market-leading quality of our tests. We believe the ability of our COVID-19 3G test to simultaneously target three separate genes within SARS-CoV-2 provides a highly accurate option for detection. This latest approval ensures we are well-positioned with our consolidated COVID-19 portfolio for any potential future outbreaks and as we continue to focus on our wider diagnostic product offering as part of our growth strategy."

    The status of the Company's current CTDA submissions is as follows:



    #

    Product name

    Current CTDA status

    1 genesig® COVID-19 Real-Time PCR

    Approved November 2021

    2 PROmate® COVID-19 2G (q32)

    Approved February 2022

    3 PROmate® COVID-19 1G (q32)

    Approved April 2022

    4 PROmate® COVID-19 1G (q16)

    Approved May 2022

    5 exsig™ COVID-19 Direct

    Approved July 2022

    6 genesig® Real-time PCR SARS-CoV-2 Winterplex

    Approved 20 October 2022

    7 Genesig® COVID-19 3G Real-Time PCR

    Approved 1 December 2022

    8

    9

    PathFlow® COVID-19 Rapid Antigen Pro

    PathFlow® COVID-19 Rapid Antigen Self-Test

    Pending evaluation

    - End -

    www.voxmarkets.co.uk/rns/announcement...
  9. forum rang 10 voda 7 december 2022 08:19
    7 Dec Non-Executive Director Change
    in Board, Novacyt Group

    Paris, France and Eastleigh, UK – 7 Dec 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Edwin Snape has informed the Board that he wishes to retire after 14 years with the expanded Group, both as a Non-Executive Director (NED) of Novacyt and formerly NED of Lab21, which was acquired by the Group in 2014. Ed’s retirement from the Board will take effect from 31 December 2022.

    James Wakefield, Chairman of Novacyt, added:

    “On behalf of the Board, I would like to thank Ed for the considerable contribution, input and support that he has provided to the Group during his 14 year tenure and wish him well with his retirement.”

    Ed Snape, NED of Novacyt, commented:

    “It has been a pleasure to have worked with so many exceptional people at Novacyt and Lab21 over the years and I would like to thank them all for their hard work and support. I look forward to watching Novacyt continue on its exciting journey to become a leading, global clinical diagnostics company in infectious diseases.”

    Non-Executive Director Change

    novacyt.com/non-executive-director-ch...
  10. forum rang 10 voda 6 januari 2023 14:30
    Novacyt S.A.

    ("Novacyt" or the "Company")

    Holdings in Company

    Paris, France and Camberley, UK - 6 January 2023 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA ("Biosynex") on 5 January 2023 that, as at 3 January 2023, Biosynex's holding in the Company on a voting and capital basis is 2.88% (2,030,916 shares).

    www.voxmarkets.co.uk/rns/announcement...
  11. forum rang 10 voda 26 januari 2023 09:15
    Novacyt S.A.
    ("Novacyt", the "Company" or the "Group")
    Full Year 2022 Trading Update

    Full year revenue and EBITDA in line with guidance
    Remain focused on post-COVID-19 growth strategy to become a leading
    global clinical diagnostics company in infectious diseases

    Paris, France and Eastleigh, UK – 26 January 2023 – Novacyt (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an
    unaudited trading update for the year ended 31 December 2022. Reported revenues and
    EBITDA for the period are both expected to be in line with guidance.
    Financial highlights1
    • Group revenue for FY2022 was £21.0m, in line with guidance, compared to
    £92.6m1
    for FY2021, due to the expected decline in COVID-19 related sales.
    • Revenue from COVID-19 products in 2022 totalled £14.7m (2021: £84.0m1).
    • Revenue for the non-COVID-19 portfolio in 2022 totalled £6.3m (2021: £8.6m1).

    As previously announced, this decline was predominantly driven by lower
    instrument sales compared to 2021 which benefited from COVID-19 demand.
    • Group EBITDA loss in FY2022 is anticipated to be circa £13.5m before exceptional
    items (2021: £3.1m1 profit) as a result of the expected decline in revenue and in
    line with guidance.
    • Cash position at 31 December 2022 was £87.0m (2021: £101.7m) and the
    Company remains debt free.
    1
    In accordance with IFRS 5, the net result of the Lab21 Products business will be reported on a separate line
    “loss from discontinued operations” in the consolidated income statement for 2021 and 2022.

    Strategic progress
    During 2022, the Company made good progress transitioning away from COVID-19
    revenue and beginning to deliver against its growth strategy, as outlined at the full year
    2021 results. This included diversification of its diagnostic portfolio through internal R&D,
    such as the enhancement of its integrated and scalable molecular workflow capability and
    a focus on high growth target infectious disease areas, as well as through strategic
    partnerships, such as the distribution agreement signed with Clonit srl, which provided
    Novacyt with immediate access to over 40 CE marked assays. At the same time, the
    Company relaunched its extensive research-use-only portfolio and has continued to be a
    global first responder in infectious diseases.

    In addition, following a strategic review of the business in 2022, the Company completed
    the closure of the Lab21 Healthcare and Microgen Bioproducts businesses to focus on core
    capabilities and operations. As a result, Novacyt remains well positioned for future growth
    and to become a leading global clinical diagnostics company focused on unmet needs in
    infectious diseases.

    2023 outlook
    The Company intends to announce its 2022 audited full year results in the week
    commencing 24 April 2023 and will provide an update on the full year 2023 outlook at this time.

    The information contained within this Announcement is deemed by the Company to constitute inside information
    as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of
    the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended).
    Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now
    considered to be in the public domain.

    novacyt.com/wp-content/uploads/2023/0...
  12. forum rang 10 voda 30 januari 2023 09:09
    30 Jan DHSC Claim update – Trial date listed

    Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt that the hearing of the case between Primer Design Ltd / Novacyt and the DHSC has been listed to commence on 10 June 2024 and is expected to last 16 days.

    DHSC Claim update

    novacyt.com/wp-content/uploads/2023/0...
  13. forum rang 10 voda 17 april 2023 08:30
    Novacyt S.A.

    ("Novacyt", the "Company" or the "Group")

    Notice of Full Year 2022 Results and Investor Presentation


    Paris, France and Eastleigh, UK - 17 April 2023 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2022 on Thursday, 27 April 2023.

    Investor webinar
    An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, and Steve Gibson, Group Finance Director, will take place at 12.00pm BST on Thursday, 27 April 2023.

    The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

    Investors can sign up to Investor Meet Company for free and add to meet NOVACYT S.A. via:

    www.investormeetcompany.com/novacyt-s...

    Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

    www.voxmarkets.co.uk/rns/announcement...
  14. forum rang 10 voda 27 april 2023 09:04
    Full year 2022 results

    Full year revenue and EBITDA in line with guidance
    Accelerating product development post-COVID-19 to become a leading
    global clinical diagnostic company in infectious diseases

    Paris, France and Eastleigh, UK 27 April 2023 – Novacyt (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its
    audited results for the year ended 31 December 2022.

    Operational highlights

    Non-COVID-19 assay development
    • Completed the development of genesig™PLEX, a multiplex gastrointestinal
    bacterial assay, available as a research-use-only test (RUO)
    • Developed and relaunched two single analyte transplant viral assay panels for the
    Epstein-Barr virus and BK virus for use on open instrument platforms
    • Augmented product portfolio with the addition of over 40 CE marked in vitro
    diagnostic (IVD) assays, through a third-party distribution agreement with Clonit
    srl
    • International launch and UK Coronavirus Test Device Approvals (CTDA) approval
    of genesig™ Real-time PCR SARS-CoV-2 genesig™ Winterplex panel covering RSV,
    Flu A&B and COVID-19
    • Relaunched RUO portfolio globally and developed Monkeypox and Adenovirus F41
    RUO assays to support infectious disease monitoring

    COVID-19 assay development
    • Six UK CTDA approvals in the year (including genesig™ Winterplex multiplex
    panel), taking the total number of Novacyt products approved by the CTDA to
    seven, the most of any UK-based company
    • CE marked two lyophilised PROmate™ products, enabling deployment of nearpatient COVID-19 diagnostic solution without the need for cold-chain shipping
    • CE marked PathFlow™ COVID-19 Rapid Antigen Self-Test received, one of the first
    saliva-based COVID-19 assays to be launched in the EEA and providing diagnosis
    of symptomatic and asymptomatic individuals in approximately 15 minutes
    Workflow and instrumentation development
    • Launched and CE marked CO-Prep™ Automated Liquid Handling System and
    completed validation of a nucleic acid extraction system to enhance post-COVID19 integrated sample-to-result molecular workflow solution
    • Launched two new lateral flow test (LFT) readers for use in conjunction with a broad
    range of assays within Novacyt’s Pathflow™ product portfolio, consisting of 18 non-
    COVID-19 products across sexually transmitted, gastrointestinal, respiratory and
    insect-borne infections

    Commercialisation
    • Partnered with a global fisheries company to develop solutions for testing infectious
    salmon anaemia virus and bacterial kidney disease
    • Signed a contract with a leading global non-governmental organisation (NGO) to
    support the detection of arboviruses, including dengue, Zika and Chikungunya
    • Partnered with leading healthcare company in India to develop and supply both
    reagents and instrumentation
    Post-period highlights
    • CE marked both q16 and q32 instruments
    • Validation of third-party Respiratory Infection Assays largely completed in Q1 as
    planned
    • Exclusive development agreement with Eluceda Ltd to develop novel biosensor
    technology in the fields of human and animal in vitro diagnostics, life science
    research and animal speciation
    • Completed the development of several RUO multiplex assays across
    gastrointestinal, respiratory and insect borne viruses
    • Sales to leading global NGO continues to gain momentum covering West Nile Fever,
    Hepatitis A & E, haemorrhagic fever and arboviruses (CHIK/DENG/ZIKA) with
    orders in excess of £150k

    Financial highlights
    • Group revenue for FY2022 was £21.0m, in line with guidance, (FY2021: £92.6m),
    due to the expected decline in COVID-19 related sales
    • Revenue from COVID-19 products in 2022 totalled £14.7m (FY2021: £84.0m)
    • Revenue for the non-COVID-19 portfolio in 2022 totalled £6.3m (FY2021: £8.6m).
    This decline was predominantly driven by lower instrument sales compared to
    FY2021 which benefited from COVID-19 demand
    • Group gross profit totalled £5.7m (27%) in FY2022 (FY2021: £28.2m (30%)). The
    FY2022 gross profit was reduced as a result of significant stock provisions based
    on lower forecasted COVID-19 sales in addition to writing-off stock that had not
    been provided for previously. Excluding the impact of these items, the margin
    would be in excess of 60%
    • Group EBITDA loss in FY2022 is £13.5m before exceptional items (FY2021: £3.1m
    profit) as a result of the expected decline in revenue and in line with guidance
    • Discontinued operations loss of £3.5m in FY2022 (FY2021: £3.7m loss)
    • Loss after tax increased to £25.7m in FY2022 (FY2021: £9.7m loss)
    • Cash position at 31 December 2022 was £87.0m (2021: £101.7m) and the
    Company remains debt free

    Voor meer, zie link:

    novacyt.com/wp-content/uploads/2023/0...
  15. forum rang 10 voda 10 mei 2023 08:47
    Novacyt S.A.

    ("Novacyt" or the "Company")

    Notice of Annual General Meeting

    Paris, France and Eastleigh, UK – 10 May 2023 – Novacyt S.A. (EURONEXT GROWTH:
    ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the
    Company’s Annual General Meeting (“AGM”) will be held at 2pm CEST/1pm BST on 15
    June 2023 as an open virtual meeting. Further details of the AGM will be provided to
    shareholders in due course.

    - End -

    novacyt.com/notice-of-annual-general-...
  16. forum rang 10 voda 27 mei 2023 07:58
    26 May Publication of Annual Report and AGM voting
    in Board, Novacyt Group, Uncategorized

    Paris, France and Eastleigh, UK – 26 May 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2022 has been published and uploaded to the Company’s website. The Annual Report has been posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs).

    Publication of Annual Report and AGM voting

    The Company’s Annual General Meeting (“AGM”) will be held exclusively as an open online
    meeting at 1pm BST/2pm CEST on Thursday, 15 June 2023. As usual, and in accordance
    with French corporate law, the AGM comprises both ordinary and extraordinary
    resolutions. All materials can be found at www.novacyt.com/investors.

    Shareholders are strongly encouraged to submit their votes in advance, in accordance with
    the instructions in the Notice of the AGM.

    Under French law, for the AGM and EGM meetings to be quorate at the first attempt,
    shareholders representing at least 20% of the share capital and voting rights, on ordinary
    resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions,
    must be present, represented or have voted in advance under the conditions set out below.
    Shareholders can vote in advance of the AGM by:

    • Downloading a copy of the proxy voting form from the website
    www.novacyt.com/investors, completing it and returning it together with evidence
    of their shareholding which must be in the form of a share certificate (attestation),
    either by post to the following address: 6 avenue de Provence 75452 Paris Cedex
    09, or via email to the following address: serviceproxy@cic.fr, or
    investor.relations@novacyt.com, no later than 12 June 2023 inclusive.
    • Voting on-line using the Votaccess portal www.actionnaire.cicmarketsolutions.eu if securities held on Euronext Growth are registered with any
    of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole,
    BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital,
    Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will
    be open from 26 May 2023 to 14 June 2023 2pm BST/3pm CEST.
    • Voting on-line via a broker, nominee, bank or authorised intermediary. Many
    intermediaries in the UK such as Hargreaves Lansdown are now using the
    Broadridge ProxyVote on-line voting portal.
    Shareholders can register for the AGM and access the online meeting by visiting
    www.novacytagm23.eventcaster.co.uk. Registrations must be accompanied by formal
    evidence of shareholding.

    Following registration approval, shareholders will be able to virtually attend the AGM and
    vote online during the meeting if they wish, providing formal evidence of holding has been
    provided prior to the meeting.

    Shareholders who have already voted (through a proxy, via their broker, nominee, bank,
    authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to
    attend the AGM but will not be able to vote twice.
    Following the meeting, a recording of the AGM will be available on the Company’s website
    at www.novacyt.com/investors.

    - End -

    novacyt.com/wp-content/uploads/2023/0...
  17. forum rang 10 voda 16 juni 2023 06:28
    Novacyt S.A.

    (“Novacyt”, the “Company” or the “Group”)
    Notice of rescheduled AGM
    AGM to be held in Paris on Thursday 10 August

    Paris, France and Eastleigh, UK – 15 June 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
    international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM), due
    to take place earlier today, will be rescheduled and held in person in Paris on Thursday 10 August at 1pm BST/2pm
    CEST.

    To function as a procedural meeting, the AGM requires a sufficient number of shareholder votes to constitute a
    quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been
    met, therefore, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled.
    The rescheduled AGM will be an open meeting exclusively, held in The Hilton Hotel, Paris Charles De Gaulle Airport,
    and will also be streamed online for those shareholders wishing to join virtually. The agenda will remain the same
    as in the first convening and the AGM will comprise of both ordinary and extraordinary resolutions.
    Shareholders can register to view the AGM via the online meeting platform by visiting
    www.novacytagm23.eventcaster.co.uk.

    Forms of Proxy already completed and submitted and votes cast by electronic meansfor the first AGM remain valid
    for all meetings subsequently convened with the same agenda (art. R. 225-77 of the French commercial code). Full
    details of dates concerning voting will follow in due course.

    novacyt.com/wp-content/uploads/2023/0...
  18. forum rang 10 voda 3 juli 2023 08:35
    3 July 2023

    RECOMMENDED CASH OFFER

    by

    Novacyt UK Holdings Limited

    (a wholly-owned subsidiary of Novacyt S.A.)

    for

    Yourgene Health plc

    to be effected by means of a Scheme of Arrangement

    under Part 26 of the Companies Act 2006

    Summary

    · The boards of directors of Novacyt and Yourgene are pleased to announce that they have reached agreement on the terms and conditions of a recommended cash offer to be made by Novacyt UK, a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene (the "Acquisition").

    · Under the terms of the Acquisition, each Yourgene Shareholder will be entitled to receive:

    0.522 pence in cash per Yourgene Share

    · The Acquisition values the entire issued and to be issued share capital of Yourgene at approximately £16.7 million.

    · The Acquisition Price represents a premium of approximately:

    - 167.7 per cent. to the Closing Price of 0.195 pence per Yourgene Share on 30 June 2023 (being the last Business Day prior to the date of this Announcement);

    - 111.3 per cent. to the Volume Weighted Average Price per Yourgene Share during the three-month period ended 30 June 2023 (being the last Business Day prior to the date of this Announcement;

    - 57.2 per cent. to the Volume Weighted Average Price per Yourgene Share during the six-month period ended 30 June 2023 (being the last Business Day prior to the date of this Announcement); and

    - 74.0 per cent. to the December 2022 placing price of 0.30 pence per Yourgene Share.

    · If, on or after the date of this Announcement and on or prior to the Effective Date, any dividend and/or other distribution and/or other return of capital in respect of the Yourgene Shares is declared, made, paid or becomes payable by Yourgene, Novacyt UK reserves the right to reduce the consideration payable for each Yourgene Share under the terms of the Acquisition by an amount up to the amount per Yourgene Share of such dividend and/or distribution and/or other return of capital, in which case any reference in this Announcement to the consideration payable under the terms of the Acquisition will be deemed to be a reference to the consideration as so reduced. In such circumstances, Yourgene Shareholders would be entitled to retain any such dividend and/or distribution and/or other return of capital.

    · It is intended that the Acquisition will be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act (or if Novacyt UK elects, with the consent of the Takeover Panel, by way of a Takeover Offer).

    Background to, and reasons for, the Acquisition

    · The boards of Novacyt and Novacyt UK believe that the Acquisition strongly aligns with Novacyt's post-COVID-19 strategy, set out by Novacyt in early 2022, which was focussed on the twin objectives of portfolio development and geographic expansion and included pursuing strategic M&A transactions to build scale and diversification to support the long-term growth of the business. For this reason, the boards of Novacyt and Novacyt UK therefore believe there is a compelling strategic and financial rationale for the Acquisition.

    · The Enlarged Group is expected to create a more scaled, diversified operator in the diagnostics sector. The Acquisition combines highly complementary technologies and services, with the Enlarged Group able to leverage mutual research and development capabilities for ongoing product development and portfolio enhancement to improve the customer offering.

    · The diagnostics industry, in which both Novacyt and Yourgene operate, is highly competitive, with multiple scale competitors. Continuing to invest in research and development to develop Yourgene's service and product offering over the long term requires highly targeted continued investment, which the combination of the two groups will facilitate, through utilisation of combined capital resources and commercial infrastructure.

    · Novacyt considers that customers will benefit significantly from the combination, driven by the complementary suite of diagnostic products and services of the two groups. This will enable the delivery of more integrated solutions through the efficient pooling of resources.

    · Novacyt believes that Yourgene's core NIPT offering and PCR portfolio has significant growth potential that can be further accelerated by the significant resources and investment that Novacyt can provide, given its strong financial position.

    · The Acquisition is expected to enable Novacyt to deliver significant value to customers across the combined set of businesses through streamlined technology and sharing of best operational practices to create a more robust and sustainable operating model to serve partners and customers.

    · The Novacyt Directors believe that there is significant potential for the Enlarged Group to strengthen customer relationships and cross-sell its expanded range of products and services within the combined installed base, whilst maintaining specialist capabilities in discrete competencies. In particular, Novacyt sees potential to leverage Yourgene's proprietary Ranger® Technology to differentiate the Enlarged Group's molecular diagnostics portfolio while continuing to explore further use cases within the Yourgene and Novacyt product portfolios.

    · Novacyt believes that Yourgene will reach its full potential under Novacyt's ownership, accelerating revenue growth and building long-term value for the Enlarged Group, driven by the increased investment in Yourgene that could be provided as part of the Enlarged Group.

    · The Novacyt Directors expect cost synergies to be generated through the rationalisation of duplicative functions and systems, elimination of excess facilities and combination of leadership roles within the Enlarged Group.

    · The boards of directors of Novacyt and Novacyt UK believe that the Enlarged Group will be a more attractive prospect as a consolidated entity to attract investment from a wider range of institutional investors.

    · The boards of directors of Novacyt and Novacyt UK believe that the Acquisition Price represents a full and fair value for Yourgene Shareholders. The Acquisition Price allows Yourgene Shareholders to immediately crystallise the value of their holdings, in cash, at a significant premium to the current share price of Yourgene, while not taking any of the substantial risk that remains to Yourgene as a standalone entity.

    Recommendation

    · The Yourgene Directors, who have been so advised by Stifel Nicolaus Europe Limited ("Stifel") as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. In providing its advice to the Yourgene Directors, Stifel has taken into account the commercial assessments of the Yourgene Directors. Stifel is providing independent financial advice to the Yourgene Directors for the purposes of Rule 3 of the Code.

    Voor meer, zie:

    www.lse.co.uk/rns/NCYT/recommended-ca...

    novacyt.com/wp-content/uploads/2023/0...
219 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!